Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Gynecol Oncol. 2014 Aug 27;135(2):318–324. doi: 10.1016/j.ygyno.2014.08.031

Fig. 5.

Fig. 5

Minnelide in combination with carboplatin and Taxol improves inhibition of tumor growth in vivo. Animals were randomized into 10 per group and then treated with either saline (S), Minnelide (M — 0.6 mg/kg, daily), carboplatin and Taxol (C/T, 20 mg/kg and 10 mg/kg respectively, twice a week) or Minnelide plus carboplatin and Taxol (0.6 mg/kg daily and 20 mg/kg and 10 mg/kg twice weekly) for 28 days. Kaplan–Meier survival curve for overall survival of C200 tumor bearing mice. Overall survival for control of 31.5 days (95% CI: 27–34), Minnelide of 42 days (95% CI: 41–43), carboplatin and paclitaxel of 45 days (95% CI: 34–54) and Minnelide plus carboplatin and paclitaxel of 70 days (95% CI: 47–93; p < 0.0001). An arrow shows the time of tumor cell injection (intraperitoneal) and the shaded area represents the treatment period.